title: Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Marzia
authors.initials: M
authors.lastname: Defina
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
authors.forename: Alberto
authors.initials: A
authors.lastname: Fabbri
authors.forename: Elena
authors.initials: E
authors.lastname: Marchini
authors.forename: Ida
authors.initials: I
authors.lastname: Chitarrelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Lauria
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D008558:Melphalan